pharmaceutical policy and pharmacoeconomics, economic impact of chronic diseases and aging issue, health policy and medical reform

1. Economics of genetic testing for breast cancer using 'Big Data' 2019-2020, National nature science fund (7181101283),PI；

2. Study on supply issue and strategy of health care in Beijing 2018，Beijing health commission，PI；

3. Standardization and analytical paradigm of national medicine policy surveillance system: based on big data mining of medicine 2017-2020，National nature science fund (71673004)，PI；

4. Study on goals and strategies of health expenditure control in Beijing 2016-2017，Beijing health commission，PI；

5. The long-term impacts of national essential medicine policy on access to healthcare and rational use of medicine 2013-2016，National nature science fund (71273016)，PI；

6. Study on index and surveillance of medicine policy 2015，National health commission，PI；

7. Study on construction and working mechanism of biding & purchasing platform for essential medicine 2012-2013，MOH，PI；

8. The impacts of the essential medicine Policy in China based on NCMS database 2011-2013， MOE(10YJC630332)，PI；

9. The utilization and financing of the essential medicine policy in China 2010-2012，MOH/AuID (HSS0907)，PI；

10. Comparison of the National Pharmaceutical Polices by different health security system. 2010-2012，MOH/AuID(HSS0907)，PI；

11. The methods to assess the health system’s performance, a systematic review 2009-2010，MOH，PI；

12. The effects of different pharmaceutical pricing on production and utilization of essential medicine, a systematic review 2008-2009，MOH，PI；

13. Strategies towards universal coverage: Evidence from international experience 2007，MOH，PI；

14. Study on incentives for production of National Essential Medicine 2006，MOH，PI；

15. Study on economic impacts of chronic diseases in rural China and health investment strategy 2006-2008，National nature science fund（70503001），PI。

1. Sun L, Legood R, Sadique Z, dos-Santos-Silva I, Yang L*. Breast cancer screening programme in China: does one size fit all? A cost-effectiveness analysis based on a Markov model. The Lancet, 2018;392(S2). (IF=53.254)

2. Sun L, Sadique Z, dos-Santos-Silva I, Yang L*, Legood R. Cost-effectiveness of breast cancer screening programme for women in rural China. International journal of cancer, 2019;144（10）：2586-2604.(IF= 7.36)

3. Sun L, Legood R, Sadique Z, dos-Santos-Silva I, Yang L*. Cost–effectiveness of risk-based breast cancer screening programme, China Bulletin of the World Health Organization 2018;96：568-577.( IF=6.361)

4. Wen lk, Wu JJ, Fen L, Yang L*, Qian F. Comparing the economic burden of ischemic stroke patients with and without atrial fibrillation: a retrospective study in Beijing, China. Current Medical Research and Opinion，2017,33(10): 1789-1794.(IF=2.757)

5. Yang, L., Sun, L., Wen, L. et al. Financing strategies to improve essential public health equalization and its effects in China. Int J Equity Health. (IF=1.738)

6. Yang, L, Liu, Y., Wen, L. et al. Examining the Impact of Rehospitalization on Healthcare Cost of Myocardial Infarction Patients in Beijing: a Retrospective, Observational study .Adv Ther. 2017 Jan;34(1):109-119. (IF= 2.709)

7. Yang L, Tan SC, Chen C, Wang XZ, Li XY and Yang XY. Economic Evaluation of Sevelamer versus Calcium-Based Binders in Treating Hyperphosphatemia among Patients with End-Stage Renal Disease in China. Clinical Therapeutics.2016;38(11):2462-2470.(IF= 2.947)

8. YANG WY, Zhuang YM, Li YK, Wang Q, Bian RW, Shen JG, Hammerby E and Yang L*. Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A 1 chieve observational study. Health and Quality of Life Outcomes 2014, 12:137.(IF=2.12)

9. Yang L, Christensen T, White J, Sun F. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in a chinese setting: a health economic model based on the predictive study. Value in health,2012;15(1s): S56-59. (IF=2.191).

10. Yang L, Li M, Tao LB, et al. Cost Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China. value in health.2009;12(s3):s66-69. (IF=2.191)